Short Interest in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Increases By 6.7%

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) saw a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,600,000 shares, an increase of 6.7% from the January 15th total of 1,500,000 shares. Based on an average daily volume of 2,270,000 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ITCI shares. Canaccord Genuity Group cut Intra-Cellular Therapies from a "buy" rating to a "hold" rating and lifted their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Piper Sandler restated a "neutral" rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. Finally, StockNews.com began coverage on Intra-Cellular Therapies in a report on Sunday. They issued a "hold" rating on the stock. Nine analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Intra-Cellular Therapies has a consensus rating of "Moderate Buy" and an average price target of $103.62.

Insider Activity

In other news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Intra-Cellular Therapies

Institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its stake in shares of Intra-Cellular Therapies by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock worth $1,878,000 after purchasing an additional 2,157 shares during the period. Barclays PLC grew its stake in shares of Intra-Cellular Therapies by 282.0% in the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock valued at $2,521,000 after purchasing an additional 25,435 shares during the period. Oak Ridge Investments LLC grew its stake in shares of Intra-Cellular Therapies by 74.1% in the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock valued at $1,656,000 after purchasing an additional 8,440 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Intra-Cellular Therapies by 31.9% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company's stock valued at $33,258,000 after purchasing an additional 109,892 shares during the period. Finally, Cynosure Group LLC grew its stake in shares of Intra-Cellular Therapies by 161.0% in the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company's stock valued at $1,057,000 after purchasing an additional 8,909 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Stock Down 0.0 %

Shares of NASDAQ:ITCI traded down $0.06 on Thursday, reaching $128.54. The company had a trading volume of 1,457,317 shares, compared to its average volume of 4,280,702. Intra-Cellular Therapies has a twelve month low of $62.78 and a twelve month high of $128.77. The stock has a 50-day moving average price of $108.45 and a 200 day moving average price of $89.01. The stock has a market capitalization of $13.67 billion, a P/E ratio of -147.75 and a beta of 0.72.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.